New drug duo tested for Tough-to-Treat gynecologic cancer
NCT ID NCT05147558
Summary
This study is testing whether a combination of two drugs, pembrolizumab and lenvatinib, can help control advanced uterine or ovarian carcinosarcoma, a rare and aggressive cancer. It is for up to 40 patients whose cancer has continued to grow after at least one prior chemotherapy treatment. Researchers will also check if certain signs in the blood can predict how well a patient responds to this treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UTERINE CARCINOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Basking Ridge (Limited protocol activities)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Limited protocol activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Monmouth (Limited protocol activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited protocol activities)
Rockville Centre, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (Limited protocol activities)
Harrison, New York, 10604, United States
Conditions
Explore the condition pages connected to this study.